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Preclinical Therapy
Suppression of Liver Tumor Growth and Metastasis by
Adiponectin in Nude Mice through Inhibition of Tumor
Angiogenesis and Downregulation of Rho Kinase/IFN-
Inducible Protein 10/Matrix Metalloproteinase 9 Signaling
Kwan Man1, Kevin T.P. Ng1, Aimin Xu2, Qiao Cheng1, Chung Mau Lo1, Jiang Wei Xiao1,
Bai Shun Sun1, Zophia X.H. Lim1, Jerry S. Cheung3, Ed X. Wu3, Chris K.W. Sun1,
Ronnie T.P. Poon1, and Sheung Tat Fan1
Abstract
Purpose: We aimed to investigate the effects of adiponectin on liver cancer growth and metastasis and
explore the underlying mechanisms.
Experimental Design: An orthotopic liver tumor nude mice model with distant metastatic potential
was applied. Either Ad-adiponectin (1 × 108; treatment group) or Ad-luciferase (control group) was in-
jected via portal vein after tumor implantation. Tumor growth and metastasis were monitored by Xeno-
gen In vivo Imaging System. Hepatic stellate cell activation by α-smooth muscle actin staining, microvessel
density by CD34 staining, macrophage infiltration in tumor tissue, and cell signaling leading to invasion,
migration [Rho kinase (ROCK), IFN-inducible protein 10 (IP10), and matrix metalloproteinase 9], and
angiogenesis [vascular endothelial growth factor (VEGF) and angiopoietin 1] were also compared. Tu-
mor-nontumor margin was examined under electron microscopy. Direct effects of adiponectin on liver
cancer cells and endothelial cells were further investigated by a series of functional studies.
Results: Tumor growth was significantly inhibited by adiponectin treatment, accompanied by a lower
incidence of lung metastasis. Hepatic stellate cell activation and macrophage infiltration in the liver tu-
mors were suppressed by adiponectin treatment, along with decreased microvessel density. The treatment
group had less Ki-67–positive tumor cells and downregulated protein expression of ROCK1, proline-rich
tyrosine kinase 2, and VEGF. Tumor vascular endothelial cell damage was found in the treatment group
under electron microscopy. In vitro functional study showed that adiponectin not only downregulated the
ROCK/IP10/VEGF signaling pathway but also inhibited the formation of lamellipodia, which contribute
to cell migration.
Conclusion: Adiponectin treatment significantly inhibited liver tumor growth and metastasis by sup-
pression of tumor angiogenesis and downregulation of the ROCK/IP10/matrix metalloproteinase 9 path-
way. Clin Cancer Res; 16(3); OF1–11. ©2010 AACR.
Although surgical procedures such as liver resection and
liver transplantation are first-line treatments for liver
cancer, tumor recurrence and metastasis remain to be
major problems affecting long-term disease-free survival.
Therefore, development of novel adjuvant therapies tar-
geting liver cancer growth, recurrence, and metastasis
without obvious toxicity to the liver itself is essential.
Adiponectin, a fat-derived hormone, has been shown
to have a correlation with tumor development and prog-
nosis (1, 2). Lower circulating levels of adiponectin have
been found to be an independent predictor of colorectal
cancer recurrence (3). Adiponectin can suppress hepatic
stellate cell activation that plays an important role in
angiogenesis. Hypoadiponectinemia accelerated liver tu-
mor formation in a nonalcoholic steatohepatitis mouse
model (4). It has been found that recombinant adipo-
nectin not only significantly attenuated liver steatosis
but also improved liver function by amelioration of in-
flammation (5) and rescued the marginal liver graft
from acute-phase injury (6). More recent studies have
also shown that adiponectin not only suppressed angio-
genesis by inducing endothelial cell apoptosis (7) but
also inhibited cell proliferation (8) and tumorigenesis
(9). All these suggest that adiponectin, besides being a
promising candidate for treating obesity-associated
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metabolic diseases, may be a potential candidate for
novel therapies for liver tumor growth, recurrence, and
metastasis.
Recently, there is much effort to probe the cell signal-
ing leading to tumor invasion, angiogenesis, and metas-
tasis. Rho kinase (ROCK) has shown its significant role
in regulating cytoskeletal events and contributed to the
invasion of hepatocellular carcinoma (10, 11). IFN-
inducible protein 10 (IP10), which has been shown to
promote tumor cell invasiveness in colon cancer (12)
and related to angiogenesis in uterine cervical cancers
(13), may also play potential role in hepatocellular carci-
noma invasiveness. Moreover, macrophages in tumor mi-
croenvironment also play an important role in facilitating
tumor invasion and angiogenesis (14) by secreting sever-
al inflammatory cytokines and chemokines, such as vas-
cular endothelial growth factor (VEGF) and matrix
metalloproteinase 9 (MMP9), which promote angiogene-
sis directly (15). Furthermore, in the presence of VEGF,
angiopoietins may promote tumor angiogenesis and pro-
gression in human hepatocellular carcinoma (16).There-
fore, it will be worthwhile to investigate the effect of
adiponectin on above molecular signaling of hepatocellu-
lar carcinoma progression and invasion.
In this study, we investigated the potential anticancer
effect of adiponectin on hepatocellular carcinoma
through in vitro functional studies and with novel ortho-
topic liver tumor animal models with different local and
distant metastatic potentials. The combined application
of a novel In vivo Imaging System (IVIS; Xenogen IVIS
100) and the higher-resolution 7T micro–magnetic reso-
nance imaging not only allowed longitudinal monitoring
of liver tumor growth and metastasis but also provided
accurate comparison of the tumor size. We also explored
the underlying molecular mechanisms of adiponectin in
the suppression of proliferation, invasion, migration, and
angiogenesis of liver cancer cells. The significance of this
study will hopefully open a new window to the develop-
ment of novel therapies targeting at liver cancer growth
and metastasis.
Materials and Methods
Patients. From December 2000 to November 2002, 100
patients (ages >18 years) diagnosed with hepatocellular
carcinoma, which were considered to be resectable based
on intraoperative ultrasonography without preoperative
adjuvant therapy, were included in the current study. Oth-
er 30 cases without liver cancer were selected with control.
The new tumor-node-metastasis staging and Edmonson
staging of these patients was based on the clinical and
pathologic diagnosis (17). The study protocol was ap-
proved by the Institutional Review Board of The University
of Hong Kong. Informed consent was obtained from each
patient before operation.
Cell lines. Human hepatocellular carcinoma cell lines
MHCC97L (a kind gift from Liver Cancer Institute, Fudan
University; ref. 18), Huh7 (a gift from Dr. H. Nakabayashi,
Hokkaido University School of Medicine; ref. 19), Hep3B
(American Type Culture Collection), and PLC (Japanese
Cancer Research Bank) were maintained in DMEM with
high glucose (Life Technologies) supplemented with
10% heat-inactivated fetal bovine serum (Life Technolo-
gies), 100 mg/mL penicillin G, and 50 μg/mL streptomy-
cin (Life Technologies) at 37°C in a humidified
atmosphere containing 5% CO2. MHCC97L cells were sta-
ble-labeled with the luciferase gene in chromosomes.
Briefly, cells were transfected with pGL3 vector (Promega),
and positive clones were selected according to luciferase
activity in Xenogen IVIS 100 (Xenogen; ref. 20).
Orthotopic nude mice liver tumor model. Male athymic
nude mice (BALB/c nu/nu, 4-6 weeks old) were used.
MHCC97L cells (∼6 × 105) in 0.2 mL culture medium
were injected subcutaneously into the right flank of each
nude mouse. Once the subcutaneous tumors reached 0.8
to 1 cm in diameter, they were removed and cut into cubes
∼1 to 2 mm3 in size, which were then implanted into the
left liver lobes of another group of nude mice using the
method described previously (21).
Treatment regimen, imaging analysis, and sample collec-
tion. Recombinant adenovirus (1×108 plaque-forming
units) expressing adiponectin (Ad-adiponectin, treatment
group) or luciferase (Ad-luciferase, control group; ref. 9)
was injected via the portal vein after tumor implantation.
Both the treatment group and the control group com-
prised 8 mice each. Blood samples were collected every
week from tail vein for the detection of serum levels of adi-
ponectin. Mice bearing liver tumors were checked by a
higher-resolution 7T magnetic resonance imaging scanner,
PharmaScan 70/16 (Bruker BioSpin). Liver tumor growth
and lung metastasis were monitored by Xenogen IVIS ev-
ery week. The nude mice were sacrificed at weeks 5, 6, and
7, respectively, after tumor implantation. Liver, lung, kid-
ney, and spleen suspected of tumor metastasis were sam-
pled for tissue sectioning to examine intrahepatic, lung,
kidney, and spleen metastases.
Plasma level of adiponectin. Plasma levels of adiponectin
of the nude mice and hepatocellular carcinoma patients
together with non–hepatocellular carcinoma controls were
Translational Relevance
In previous animal studies, we have already shown
that adiponectin could attenuate small-for-size fatty
liver graft injury after liver transplantation thorough
anti-inflammatory response and decrease of fatty
changes in the graft. In the present study, the antican-
cer effect of adiponectin, including suppression of tu-
mor angiogenesis and downregulation of invasive
signaling pathway, has been further confirmed in an
orthotopic liver cancer model with distant metastasis
potential. Therefore, adiponectin may have great po-
tential to suppress liver tumor recurrence after surgical
treatments including liver transplantation for liver can-
cer patients in clinical practice.
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determined using in-house RIA as described previously
(22).
Morphologic study by light and transmission electron mi-
croscopy. Liver tumor tissue including nontumor margin
was taken at different time points after tumor implanta-
tion for light microscopy with H&E staining. To compare
the ultrastructural features of the specimens from mice
from the treatment and control groups, the specimens
were immediately cut into 1-mm cubes and fixed in
2.5% glutaraldehyde in sodium carcodylate hydrochloride
buffer overnight at 4°C for electron microscopy section.
The sections were then examined under a transmission
electron microscope, Philips EM 208 (Koninklijke Philips
Electronics; ref. 23).
Gene expression of ROCK1, IP10, angiopoietin 1, MMP9,
and adiponectin receptors. Liver tumor tissue was stored at
-80°C until total RNA extraction. Total RNA was ex-
tracted using RNeasy Midi kit (Qiagen). Total RNA
(∼0.5 μg) from each sample was used to perform reverse
transcription reaction using TaqMan Reverse Transcrip-
tion Reagents (ref. 24; Applied Biosystems). Reverse tran-
scription product (1 μL) was used to perform real-time
quantitative reverse transcription-PCR using TaqMan
Core Reagent kit (Applied Biosystems) by ABI PRISM
7700 Sequence Detection System (Applied Biosystems).
Probes and primers of ROCK, IP10, angiopoietin 1,
and VEGF were purchased from Applied Biosystems. Taq-
Man rRNA Control Reagent (18S RNA probe and primer
pair; Applied Biosystems) was used for internal control in
the same PCR plate well to normalize target gene ampli-
fication copies. All samples were detected in triplicate.
Readings from each sample and its internal control were
used to calculate gene expression level. After normaliza-
tion with the internal control, gene expression levels at
different time points after liver transplantation were ex-
pressed as the folds relative to the normal liver.
The total RNA from human liver cancer cell lines
(Huh7, PLC, Hep3B, MHCC97L, and MHCC97H) was
also extracted using RNeasy Midi kit. The method for
cDNA production was the same as for liver tumor tis-
sues (24). Reverse transcription product (1 μL) was used
to perform PCR. The primer sets for adiponectin recep-
tor 1 are AdipoR1-F: CTTCTACTGCTCCCCACAGC and
AdipoR1-R: GGTGCTTAGGAGTGGCAAAC. The primer
sets for adiponectin receptor 2 are AdipoR2-F:
TGTTTCGCCCAAATATCTCC and Ad ipoR2 -R :
CTGTGTGGAAGAGCCATGAA.
Protein expression of ROCK, IP10, VEGF, Akt, Bcl-2,
BAX, and p53. Western blot was done with a modified
version of a method described previously (25). Immu-
noreactive signals were visualized with ECL Plus Western
Blotting Detection Reagents (Amersham Biosciences)
and quantified by scanning densitometry (Syngene).
Anti–ROCK-1, anti-0IP10, and anti-VEGF antibodies
were purchased from Santa Cruz Biotechnology. Anti-
Akt, anti–phospho-Akt (Ser473), anti–Bcl-2, anti-BAX,
and anti–phospho-p53 (Ser15) antibodies were from
Cell Signaling Technology.
Plasma levels of VEGF by ELISA. Circulating VEGF levels
were detected by ELISA on plasma samples using Quanti-
kine Mouse VEGF Immunoassay kit (R&D Systems) in ac-
cordance with a previously described method (26).
Protein expression of VEGF/proline-rich tyrosine kinase 2
and activation of macrophages and hepatic stellate cells. Par-
affin sections (4 μm thick) were dewaxed in xylene, rinsed
in grade alcohol, and rehydrated in water and then were
placed in citric buffer (pH 6.0) and treated in a microwave
oven with high power for 3 min and subsequent low pow-
er for 10 min. Afterwards, the sections underwent blocking
with 3% peroxidase for 20 min and 10% goat serum for
30 min. Subsequently, primary antibodies with proper di-
lution were applied on the sections, which were then incu-
bated at 4°C overnight. Following that, secondary
antibodies from Dako EnVision System (DakoCytoma-
tion) were applied, and the sections were incubated for
30 min at room temperature. Signals were developed with
3,3′-diaminobenzidine substrate solution (DakoCytoma-
tion). The sections were finally counterstained by hema-
toxylin solution. Primary antibodies used in this study
included VEGF (Santa Cruz Biotechnology), α-smooth
muscle actin (DakoCytomation), CD34 (Santa Cruz Bio-
technology), proline-rich tyrosine kinase 2 (Pyk2), and
CD68 (BD Biosciences).
Determination of microvessel density. Microvessel density
(MVD) of liver tumor tissue sections was evaluated (27).
Any CD34+ stained endothelial cell or endothelial cell
cluster that was clearly separated from adjacent microves-
sels, tumor cells, and connective elements was counted as
one microvessel. The mean microvessel count of the five
most vascular areas was taken as the MVD, which was ex-
pressed as the absolute number of microvessels per 1.485
mm2 (×200 field).
Determination of tumor cell apoptosis by terminal deoxy-
nucleotidyl transferase–mediated dUTP nick end labeling as-
say. Paraffin sections of liver biopsies from the treatment
and control groups were detected for apoptotic cells by In
Situ Cell Death Detection kit (Roche Molecular Biochem-
icals, Roche Applied Science) according to the manufac-
turer’s protocol.
Tube formation assay. Liquefied Matrigel (BD Bios-
ciences) was used to coat the surface of the wells of a
96-well plate and allowed to solidify in a culture incubator
at 37°C for 4 h. Each 30,000 cells of mouse endothelial
cell line CRL2279 (American Type Culture Collection)
were seeded into the precoated wells of the 96-well plate.
Recombinant adiponectin protein generated from human
embryonic kidney cells (5) was administered to the endo-
thelial cells at the concentration of 0 or 30 μg/mL. Appear-
ance of the cells on Matrigel was captured by digital
camera after 24 and 48 h.
Ultrastructure of tumor cells under scanning electron mi-
croscopy. Tumor cells with or without adiponectin treat-
ment grown on sterile round glass coverslips were fixed
with 2.5% glutaraldehyde in 0.1 mol/L sodium cacody-
late-HCl buffer (pH 7.4), quenched with 0.1 mol/L su-
crose/cacodylate solution, and washed in cacolydate
Adiponectin Suppresses Liver Tumor Growth Q1
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buffer. The samples were then postfixed with 1% OsO4 in
cacodylate buffer. After a cacodylate buffer wash, they were
dehydrated through a graded series of ethanol washes fol-
lowed by critical point drying using BAL-TEC CPD 030
Critical Point Dryer (BAL-TEC). The samples were then
sputter-coated with a layer of gold using BAL-TEC SCD
005 Sputter Coater (BAL-TEC) and visualized using Leica
Cambridge Stereoscan 440 SEM (Leica) at an accelerating
voltage of 12 kV.
Statistical analysis. Continuous variables were expressed
as median with range. Mann-Whitney U test was used for
statistical comparison. χ2 test was used to compare inci-
dence of lung metastasis in the nude mice orthotopic liver
tumor model and to compare incidence of venous inva-
sion as well as incidence of tumor thrombus in the rat
transplantation model. Calculations were made with SPSS
computer software (SPSS).
Results
Plasma levels of adiponectin were decreased in hepatocel-
lular carcinoma patients. Preoperative plasma levels of
adiponectin of the hepatocellular carcinoma patients
were significantly decreased compared with that of the
non–hepatocellular carcinoma controls [11.04 (0-48.24)
versus 30.85 (0-46.32) μg/mL; P = 0.000;F1 Fig. 1A]. How-
ever, there was no statistical difference of the correlation
among the adiponectin levels and clinicopathologic
parameters in the hepatocellular carcinoma patients.
Ad-adiponectin injection significantly increased circulat-
ing adiponectin levels during the first 5 weeks after treat-
ment. Without Ad-adiponectin treatment, circulating
adiponectin levels were constantly maintained at ∼15
μg/mL (Fig. 1B). Ad-adiponectin portal vein injection sig-
nificantly increased circulating adiponectin levels during
the whole duration after treatment. The levels increased
to ∼3-fold compared with those in the control group in
the first 7 days and reached the peak level (6-fold) at
day 21 after treatment. Consistently higher circulating le-
vels of adiponectin played an important role in inhibition
of liver tumor growth and metastasis as shown in Fig. 1C
and D.
Adiponectin significantly suppressed liver tumor growth
and metastasis. Liver tumor growth and metastasis were
compared between animals with and without adiponectin
treatment. Direct measurement of tumor volume was
done at weeks 5, 6, and 7 after orthotopic tumor implan-
tation (Fig. 1C; T1Table 1). Longitudinal monitoring of tu-
mor growth and metastasis by Xenogen IVIS and 7T
micro–magnetic resonance imaging (Fig. 1D) showed that
adiponectin significantly inhibited liver tumor growth and
lung metastasis after treatment. Local metastasis (intrahe-
patic) and distant metastasis (lung) were confirmed by
histology examination (Fig. 1D). Magnetic resonance im-
aging scanning also showed the significant decrease of tu-
mor size at week 7 after tumor implantation (Fig. 1D).
After adiponectin treatment, incidence of intrahepatic me-
tastasis decreased from 87.5% (7 of 8) to 25% (2 of 8; P =
0.041). Similarly, there was significant inhibition of lung
metastasis by adiponectin treatment, manifested by a drop
of incidence from 75% (6 of 8) to 12.5% (1 of 8; P =
0.041).
Adiponectin attenuated invasive growth pattern of tumor.
Under light microscope examination ( F2Fig. 2A), invasive tu-
mor growth patterns manifested by the presence of tumor
thrombus, intrahepatic metastasis, and lung metastatic
Table 1. Comparison of tumor volume and MVD-CD34 of the tumor from mice with or without adiponec-
tin treatment
Time duration after tumor implantation Treatment (n = 8) Control (n = 8) P
5 wk, tumor volume (mm3) 25.4 (6-75) 936 (500-1,267.5) 0.002
6 wk, tumor volume (mm3) 81.25 (6-198) 1,143 (75-2,176) 0.009
7 wk, tumor volume (mm3) 75 (40-125) 2,560 (1,600-3,260) 0.002
5 wk, MVD-CD34/1.485 mm2 7.52 (4.67-11.7) 38.72 (38-39.8) 0.006
6 wk, MVD-CD34/1.485 mm2 6 (2-11.25) 28 (15-37) 0.000
7 wk, MVD-CD34/1.485 mm2 8.25 (4-9) 35.6 (26.5-52.7) 0.004
NOTE: Median (range).
Fig. 1. A, comparison of plasma levels of adiponectin between hepatocellular carcinoma patients and non–hepatocellular carcinoma controls. Significantly
lower levels of adiponectin were found in hepatocellular carcinoma patients (P < 0.001). B, comparison of plasma adiponectin levels of mice with and
without adiponectin treatment at different time points after tumor implantation. Significantly higher levels of adiponectin were found during the 49 days after
tumor implantation. *, P < 0.01, compared with control group. C, comparison of in situ tumor growth and tumor volume with and without adiponectin
treatment in an orthotopic liver tumor nude mice model at weeks 5, 6, and 7 after tumor implantation. D, monitoring of in situ tumor growth by Xenogen
IVIS at different time points after tumor implantation. Orthotopic liver tumor growth and lung metastasis was inhibited by adiponectin treatment.
Representative magnetic resonance imaging at week 7 after tumor implantation showed the difference of tumor size between mice with and without
adiponectin treatment. The liver tumor shows hyperdensity compared with normal tissues.
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nodules were shown in the control group. After adiponec-
tin treatment, clear demarcation between tumor tissue and
nontumor tissue was present together with obvious tumor
necrosis. Consistently, ultrastructural changes (Fig. 2B) in
liver tumor tissue and nontumor tissue were obvious after
adiponectin treatment. In the control group where intrahe-
patic metastasis was seen (Fig. 2B-1), tumor endothelial
cells were intact (Fig. 2B-2) and tumor cells invaded blood
vessels directly (Fig. 2B-3). In the treatment group, clear
margin between tumor cells and liver cells was observed
(Fig. 2B-4), and disruption of tumor endothelial cells
(Fig. 2B-5 and 6) was shown in most of the cases. The dis-
ruption of tumor endothelial cells might have contributed
to inhibition of tumor angiogenesis.
Adiponectin significantly attenuated hepatic stellate cell
activation and decreased MVD. Hepatic stellate cell activa-
tion in liver tumors was considered to be related to tu-
mor angiogenesis (28). Without adiponectin treatment,
remarkable activation of hepatic stellate cells indicated
by α-smooth muscle actin staining was found in the liv-
er tumors at different time points after tumor implanta-
tion ( F3Fig. 3A). Adiponectin treatment significantly inhibited
the hepatic stellate cell activation in the liver tumors
(Fig. 3A). Consistently, tumor MVD calculated by new vessel
formation using CD34 staining decreased significantly after
adiponectin treatment (Fig. 3B; Table 1).
Adiponectin suppressed Pyk2 expression and induced tu-
mor cell apoptosis. Pyk2 has recently been found to be re-
lating to liver tumor invasion and poor prognosis in
clinical study (29) and to promote proliferation and inva-
siveness of hepatocellular carcinoma cells through c-Src/
extracellular signal-regulated kinase activation (20, 23).
In the current animal study, intracellular protein expres-
sion of Pyk2 in liver tumors was downregulated by adipo-
nectin at different time points after treatment (Fig. 3C).
Furthermore, adiponectin treatment induced significant
tumor cell apoptosis compared with the control group
(Fig. 3D) at different time points.
Adiponectin downregulated ROCK/IP10/angiopoietin 1/
MMP9/VEGF cell signaling in tumor tissue. mRNA expres-
sion levels of ROCK, IP10, angiopoietin 1, and MMP9
in liver tumor tissue were compared between mice with
Fig. 2. A, histologic features of liver tumors
from mice with and without adiponectin
treatment. Invasive growth pattern together
with tumor thrombus (arrowheads) was
found in the control group. Lung metastatic
nodule (T) was also present in the control
group. In the treatment group, obvious
tumor necrosis was present (arrows). B,
ultrastructure of liver tumor by electron
microscopy. Invasive tumor growth (1) and
intact tumor endothelial cells (2) together
with direct tumor cell invasion to blood
vessel (3) were found in the control group.
After adiponectin treatment, clear margin
between tumor and nontumor cells (4)
together disruption of tumor endothelial
cells (5 and 6) was shown in the treatment
group.
Man et al.
Clin Cancer Res; 16(3) February 1, 2010 Clinical Cancer ResearchOF6
and without treatment (F4 Fig. 4A). There were 6 animals
included in each group for the analysis. Adiponectin sig-
nificantly downregulated gene expression levels of
ROCK, IP10, angiopoietin 1, and MMP9 in liver tumors
at different time points after treatment. Consistently,
protein expression of ROCK1 and VEGF was also found
downregulated after adiponectin treatment by Western
blot (Fig. 4B). In the control group, during the 5 to 7
weeks after tumor implantation, immunostaining re-
vealed strong signals of intracellular protein expression
of VEGF in the liver tumors (Fig. 4C). On the contrary,
only weak VEGF expression was detected together with
tumor necrosis in the treatment group. Consistently, cir-
culating serum VEGF levels descended significantly at
weeks 5, 6, and 7 in the treatment group (Fig. 4D).
Consistent with the downregulation of cell signaling
leading to tumor cell invasion and angiogenesis, tu-
mor-associated macrophage infiltration was also de-
creased after adiponectin treatment (Fig. 4C).
Effect of adiponectin on apoptotic signaling and ROCK/
IP10/VEGF pathway in liver cancer cells and inhibition
of tube formation of tumor endothelial cells. Adiponectin
Fig. 3. A, comparison of hepatic
stellate cell activation in liver tumors
from mice with and without
treatment was detected by
immunostaining of α-smooth
muscle actin. 1 and 2, control
group; 3 and 4, treatment group. B,
comparison of MVD by CD34+
tumor endothelial cells by
immunostaining between mice with
and without treatment. 1 and 2,
control group; 3 and 4, treatment
group. C, intracellular protein
expression of Pyk2 in liver tumor
was examined by immunostaining.
1 and 2, control group; 3 and 4,
treatment group. D, tumor cell
apoptosis was compared by
terminal deoxynucleotidyl
transferase–mediated dUTP nick
end labeling staining. Comparison
of apoptotic tumor cells of mice with
and without treatment at different
time points. 1 and 2, control group;
3 and 4, treatment group. *,
P < 0.05, comparison between
treatment and control groups.
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receptors 1 and 2 were expressed in all human liver can-
cer cell lines in the current study (F5 Fig. 5A-1). The gene
expression levels of these two receptors were consistent
after adiponectin administration (with similar expression
levels by real-time quantitative reverse transcription-PCR;
data no shown). The effect of adiponectin on apoptotic
signaling of PLC (invasive hepatocellular carcinoma cell
line) and MHCC97L (metastatic cell line) cells were in-
vestigated by Western blot (Fig. 5A-2). The downregula-
tion of Akt signal and upregulation of BAX/P53 were
mainly found in PLC cell line. Adiponectin administra-
tion (of both adenovirus and protein) downregulated
the protein expression of ROCK, IP10, and VEGF in
MHCC97L liver tumor cells in a dose-dependent man-
ner (Fig. 5B). Adiponectin protein also inhibited the
tube formation ability of mouse endothelial cells (cell
line CRL2279) in tube formation assay (Fig. 5C).
Adiponectin treatment decreased lamellipodial formation
on tumor cell surface. Without adiponectin treatment, ob-
vious lamellipodial formation was found on MHCC97L
liver tumor cell surface (Fig. 5D). After administration of
adiponectin protein at different concentrations, forma-
tion of lamellipodia was inhibited on tumor cell surface
(Fig. 5D).
Fig. 4. A, gene expression of cell signaling
leading to tumor invasion and angiogenesis in
tumor tissue detected by real-time quantitative
reverse transcription-PCR. B, protein
expression of VEGF and ROCK1 in liver tumor
detected by Western blot. C, intracellular
protein expression of VEGF and macrophage
infiltration (ED1 staining) in the liver tumor.
D, serum levels of circulating VEGF were
compared by quantitative ELISA. *, P < 0.05,
compared with control group. There were
6 animals included in each group for analysis.
Man et al.
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Discussion
Recent clinical case-control studies have shown the signif-
icant association between lower circulating adiponectin le-
vels and poor prognosis (1). It has also been reported that
hypoadiponectinemia promoted tumorigenesis in a mouse
liver tumor model with nonalcoholic steatohepatitis (4). In
our clinical series, significant lower plasma levels of adipo-
nectin were found in the hepatocellular carcinoma patients
compared with the non–hepatocellular carcinoma controls.
Fig. 5. A-1, gene expression of adiponectin receptors 1 and 2 in different liver cancer cell lines. 1, PLC; 2, Huh7; 3, Hep3B; 4, MHCC97L; 5, MHCC97H; 6,
negative control. A-2, cell signaling leading to apoptosis was compared in PLC and MHCC97L cell lines under 5, 10, and 30 μg adiponectin protein
administration for 24 h. B, protein expression of ROCK, IP10, and VEGF was compared in MHCC97L cells under adiponectin treatment. Ad-ad, adenovirus
with adiponectin expression. There were 6 animals included in each group for analysis. C, comparison of tube formation in mouse endothelial cells
(cell line CRL2279) with or without adiponectin administration. D, comparison of lamellipodial formation on tumor cell surface. Without adiponectin
treatment, obvious lamellipodial formation was found on MHCC97L liver tumor cell surface (a and b). After administration of adiponectin protein
at concentrations of 50 μg (c and d), only a few lamellipodia were formed on the tumor cell surface.Q2
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Therefore, it is worthwhile to study the anticancer effect of
adiponectin on liver tumor growth andmetastasis and to ex-
plore the underlying molecular mechanism therein.
In this study, the significant effect of adiponectin in in-
hibition of tumor growth and metastasis was first shown
in an orthotopic liver tumor model with distant metastatic
potential. With the application of Xenogen IVIS and high-
er-resolution micro–magnetic resonance imaging, remark-
able suppression of in situ liver tumor growth by
adiponectin treatment was shown longitudinally at differ-
ent time points. In addition to the inhibition of liver tu-
mor growth, adiponectin treatment also significantly
decreased the incidence of local and distant metastasis.
Consistent with the phenotype of tumor growth and me-
tastasis, histologic finding also showed that invasive
growth pattern, the manifestation of which included tu-
mor thrombus and intrahepatic metastasis, was mainly
present in the control group. After adiponectin treatment,
obvious tumor necrosis and clear margin between tumor
and nontumor were observed. Electron microscopy re-
vealed that adiponectin treatment destroyed the integrity
of tumor endothelial cells. This phenomenon was consis-
tent with the presence of suppression of tumor angiogen-
esis. Without treatment, tumor ultrastructure showed
capillarized sinusoids and tumor cells were invading ves-
sels, two typical features linked to tumor angiogenesis and
invasiveness (30, 31).
In the study, suppression of tumor growth, invasiveness,
and angiogenesis might have been directly caused by the
downregulation of liver tumor gene expression profiles by
adiponectin. Such profiles prompt cell invasion and migra-
tion signaling IP10/ROCK/Pyk2 (12, 28, 29, 32–34). When
comparing the treatment and control groups, it was found
that, in addition to the effects of adiponectin on cell signal-
ing leading to invasion and migration, adiponectin also in-
hibited tumor-associated macrophage infiltration in liver
tumors. Macrophages in tumor microenvironment play
an important role in facilitating tumor invasion and angio-
genesis (14) by secreting several inflammatory cytokines
and chemokines, such as VEGF andMMP9, which promote
angiogenesis directly (15). The phenomenon of inhibition
of tumor-associated macrophages by adiponectin was con-
sistent with the downregulation of VEGF andMMP9 expres-
sions in tumor tissue. It was also consistent with the
decrease of MVD and the attenuation of tumor-associated
hepatic stellate cell activation, which are also considered
to play direct roles in tumor angiogenesis and metastasis
(28, 35). Furthermore, significantly lower circulating VEGF
levels were also shown in the current in vivo animal model.
Obviously, liver tumor growth and metastasis were signifi-
cantly suppressed by adiponectin treatment.
The direct effect of adiponectin in inhibition of liver tu-
mor invasion and angiogenesis was further confirmed in
our current in vitro functional studies. The in vitro function-
al studies clearly indicated that adiponectin directly di-
minished lamellipodial formation on cell surface, which
is the typical characteristic leading to cell motility (36).
In addition to the alteration of tumor cell surface structure,
adiponectin also downregulated intracellular protein le-
vels of IP10/ROCK/VEGF in a dose-dependent manner.
This finding was consistent with the phenotype of our an-
imal models with suppressed tumor growth and metasta-
sis. Furthermore, adiponectin not only targeted liver
tumor cells directly but also inhibited tube formation of
endothelial cells, which is involved in tumor angiogenesis.
It was further confirmed that adiponectin suppressed tu-
mor angiogenesis in the current orthotopic liver cancer
mouse model. Although the significant apoptosis of tu-
mor cells was found after adiponectin treatment in the an-
imal model, the in vitro functional study in MHCC97L did
not confirm the downregulation of Akt signaling by adipo-
nectin. Therefore, the induction of apoptosis by adiponec-
tin might be the secondary effect from antiangiogenesis
rather than its direct effect in MHCC97L cells. However,
the downregulation of Akt signal and upregulation of
BAX/P53 were found in PLC cell line. It suggested that
the effect of adiponectin-inducing apoptosis might be cell
line dependent.
In conclusion, adiponectin has shown its great potential
in suppression of liver tumor growth and metastasis
through downregulation of cell signaling leading to inva-
sion and angiogenesis. In addition, it inhibits tumor in-
flammatory response by suppressing tumor-associated
macrophage infiltration. These suggest that adiponectin
may be a promising candidate for potential adjuvant ther-
apies for treating liver cancer before or after liver surgery in
prevention of late-phase tumor recurrence.
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